https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-announces-financial-results-for-the-third-lurzz16wsc8u.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-announces-financial-results-for-the-third-lurzz16wsc8u.html?utm_source=stocktitan-bluesky&utm_medium=social
#gay
#gay
🩷 7:26 🩵ARMP
🩷 7:26 🩵ARMP
www.revelionart.store/product/armp...
www.revelionart.store/product/armp...
L’Autorité de régulation des marchés publics (ARMP) connaît un changement de direction. Le jeudi 8 septembre 2026, Brahim Bechir Mourtallah a officiellement pris ses fonctions de directeur général.
#JournalDuTchad #Tchad #ARMP
L’Autorité de régulation des marchés publics (ARMP) connaît un changement de direction. Le jeudi 8 septembre 2026, Brahim Bechir Mourtallah a officiellement pris ses fonctions de directeur général.
#JournalDuTchad #Tchad #ARMP
prismmarketview.com/armata-stren...
prismmarketview.com/armata-stren...
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-strengthens-intellectual-property-portfolio-lg6vwvhgtc2x.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-strengthens-intellectual-property-portfolio-lg6vwvhgtc2x.html?utm_source=stocktitan-bluesky&utm_medium=social
On September 23, 2026, Armata Pharmaceuticals, Inc. issued a press release announcing that it has received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support activities associated with the Phase 3 development program for AP-SA02, the Company’s intra...
On September 23, 2026, Armata Pharmaceuticals, Inc. issued a press release announcing that it has received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support activities associated with the Phase 3 development program for AP-SA02, the Company’s intra...
prismmarketview.com/armata-pharm...
prismmarketview.com/armata-pharm...
prismmarketview.com/armatas-ap-s...
prismmarketview.com/armatas-ap-s...
$CNTB asthma endpoint miss; $BIVI exploratory Long COVID signals; $CRBP obesity data; $ARMP FDA designation. Evidence, limits and next catalysts.
https://www.merlintrader.com/biotech-radar-september-15-2026-cntb-bivi-crbp-armp/
$CNTB asthma endpoint miss; $BIVI exploratory Long COVID signals; $CRBP obesity data; $ARMP FDA designation. Evidence, limits and next catalysts.
https://www.merlintrader.com/biotech-radar-september-15-2026-cntb-bivi-crbp-armp/
On September 14, 2026, Armata Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, the Company’s intravenously administered Staphylococcus aureus multi-phage product candidate, for the a...
On September 14, 2026, Armata Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, the Company’s intravenously administered Staphylococcus aureus multi-phage product candidate, for the a...
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-receives-u-s-fda-breakthrough-therapy-fk6gc9x3mwt1.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-receives-u-s-fda-breakthrough-therapy-fk6gc9x3mwt1.html?utm_source=stocktitan-bluesky&utm_medium=social